JP2013173782A5 - - Google Patents

Download PDF

Info

Publication number
JP2013173782A5
JP2013173782A5 JP2013097487A JP2013097487A JP2013173782A5 JP 2013173782 A5 JP2013173782 A5 JP 2013173782A5 JP 2013097487 A JP2013097487 A JP 2013097487A JP 2013097487 A JP2013097487 A JP 2013097487A JP 2013173782 A5 JP2013173782 A5 JP 2013173782A5
Authority
JP
Japan
Prior art keywords
fluoro
pregnan
pregnane
oxime
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013097487A
Other languages
English (en)
Other versions
JP5657052B2 (ja
JP2013173782A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013173782A publication Critical patent/JP2013173782A/ja
Publication of JP2013173782A5 publication Critical patent/JP2013173782A5/ja
Application granted granted Critical
Publication of JP5657052B2 publication Critical patent/JP5657052B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (1)

  1. 3β−フルオロ,5β−プレグナン−20−(R)−オール、
    3β−フルオロ,5β−プレグナン−20−(S)−オール、
    3β−フルオロ,5α−プレグナン−20−オン、
    3α−フルオロ,5α−プレグナン−20−(R)−オール、
    3α−フルオロ,5α−プレグナン−20−オンオキシム、および
    3β−フルオロ,5α−プレグナン−20−オンオキシム、
    または薬学的に許容されるその塩、もしくは溶媒和物の中から選択される化合物。
JP2013097487A 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 Active JP5657052B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86065806P 2006-11-21 2006-11-21
US60/860,658 2006-11-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009537124A Division JP5386362B2 (ja) 2006-11-21 2007-11-20 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用

Publications (3)

Publication Number Publication Date
JP2013173782A JP2013173782A (ja) 2013-09-05
JP2013173782A5 true JP2013173782A5 (ja) 2013-10-17
JP5657052B2 JP5657052B2 (ja) 2015-01-21

Family

ID=39429970

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009537124A Expired - Fee Related JP5386362B2 (ja) 2006-11-21 2007-11-20 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2013097486A Active JP5918170B2 (ja) 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2013097485A Pending JP2013173781A (ja) 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2013097487A Active JP5657052B2 (ja) 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2015047791A Pending JP2015147774A (ja) 2006-11-21 2015-03-11 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2009537124A Expired - Fee Related JP5386362B2 (ja) 2006-11-21 2007-11-20 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2013097486A Active JP5918170B2 (ja) 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2013097485A Pending JP2013173781A (ja) 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015047791A Pending JP2015147774A (ja) 2006-11-21 2015-03-11 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用

Country Status (16)

Country Link
US (9) US8580983B2 (ja)
EP (4) EP2097437B1 (ja)
JP (5) JP5386362B2 (ja)
AU (1) AU2007322423C1 (ja)
BR (2) BRPI0718945B8 (ja)
CA (2) CA2664126C (ja)
DK (3) DK2711371T3 (ja)
ES (3) ES2607852T3 (ja)
HU (3) HUE036410T2 (ja)
IN (1) IN2014DN02014A (ja)
MX (1) MX2009005335A (ja)
PL (3) PL2792681T3 (ja)
PT (1) PT2097437E (ja)
RU (1) RU2458065C2 (ja)
SI (1) SI2097437T1 (ja)
WO (1) WO2008063128A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2711371T3 (en) 2006-11-21 2018-04-16 Asarina Pharma Ab Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
ES2566765T3 (es) 2010-01-14 2016-04-15 Asarina Pharma Ab Una composición farmacéutica que contiene 3-beta-hidroxi-5-alfa-pregnan-20-ona con propiedades de almacenamiento y solubilidad mejoradas
WO2011138460A1 (en) * 2010-05-07 2011-11-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Progesterone receptor antagonists and uses thereof
US10259839B2 (en) * 2012-11-28 2019-04-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) 3-(4′-substituted)-benzyl-ether derivatives of pregnenolone
SI3461834T1 (sl) 2013-03-13 2021-11-30 Sage Therapeutics, Inc. Nevroaktivni steroidi
MX2016008851A (es) * 2014-01-29 2017-03-23 Umecrine Cognition Ab Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.
SI3224269T1 (sl) * 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ab公司 新穎化合物
WO2017007840A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DE102015120587A1 (de) 2015-11-26 2017-06-01 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden
PL3436022T3 (pl) 2016-04-01 2022-08-08 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
MA46566A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
WO2018075698A1 (en) 2016-10-18 2018-04-26 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
BR112019015362A2 (pt) 2017-02-10 2020-10-20 Asarina Pharma Ab 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso em tratamento médico
MX2020005442A (es) 2017-11-27 2022-03-30 Umecrine Cognition Ab FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA.
MX2020010219A (es) 2018-04-05 2020-11-09 Asarina Pharma Aps Antagonistas de gaba-a para tratar trastornos por abstinencia de sustancia.
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
CA3237550A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083979A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463755A (fr) * 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3152121A (en) 1962-03-16 1964-10-06 Upjohn Co 20-ketals of 3-hydroxy-5 beta-pregnan-20-one
CH491889A (de) 1966-10-22 1970-06-15 Richter Gedeon Vegyeszet Verfahren zur Herstellung von Steroiden
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5234603A (en) 1991-06-04 1993-08-10 Analytical Development Corporation Methods employing a zirconium salt for use in wastewater treatment
DE69435286D1 (de) * 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
NZ282939A (en) * 1994-02-14 1998-08-26 Cocensys Inc Androstanes and pregnanes for allosteric modulation of gaba receptors
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
CN1171114A (zh) * 1994-11-23 1998-01-21 科斯赛斯公司 用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系
ATE284895T1 (de) * 1995-06-06 2005-01-15 Euro Celtique Sa Neuroaktive steroide der androstan- und pregnanreihe
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
ATE307592T1 (de) 1998-03-11 2005-11-15 Torbjoern Backstroem Epiallopregnanolon zur behandlung von krankheiten des cns
WO1999052532A1 (en) 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ294278B6 (cs) * 1999-11-25 2004-11-10 Ústav organické chemie a biochemie AV ČR Neuroaktivní steroidy a způsob jejich přípravy
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
FR2831441B1 (fr) 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
EP1310258A1 (en) 2001-11-08 2003-05-14 Etienne-Emile Baulieu Enantiomers of steroids for the enhancement of memory and cognitive function
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
CA2585359C (en) * 2004-11-18 2013-01-08 Umecrine Ab Gaba-steroid antagonists and their use for the treatment of cns disorders
DK2711371T3 (en) 2006-11-21 2018-04-16 Asarina Pharma Ab Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders
WO2011138460A1 (en) 2010-05-07 2011-11-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Progesterone receptor antagonists and uses thereof

Similar Documents

Publication Publication Date Title
JP2013173782A5 (ja)
JP2013173781A5 (ja)
JP2015147774A5 (ja)
NO2024001I1 (no) Ritlecitinib, or a pharmaceutically acceptable salt thereof
JP2016028092A5 (ja)
JP2016065085A5 (ja)
JP2015081257A5 (ja)
JP2012107057A5 (ja)
JP2016502162A5 (ja)
JP2016000169A5 (ja)
JP2015528502A5 (ja)
JP2017137500A5 (ja)
JP2015503422A5 (ja)
JP2015525757A5 (ja)
JP2014156468A5 (ja)
JP2014501485A5 (ja)
JP2015125255A5 (ja)
JP2015053052A5 (ja)
JP2017005051A5 (ja)
JP2017508572A5 (ja)
JP2011170856A5 (ja)
JP2013543797A5 (ja)
JP2015504870A5 (ja)
JP2013253099A5 (ja)
CY1121464T1 (el) Στεροειδης ενωση για χρηση στην αντιμετωπιση της ηπατικης εγκεφαλοπαθειας